Literature DB >> 12509129

Transgenesis applied to transmissible spongiform encephalopathies.

Jean-Luc Vilotte1, Hubert Laude.   

Abstract

Transmissible spongiform encephalopathies (TSE) are fatal neurodegenerative disorders present in various mammals. TSEs have been studies intensively, even more so following the BSE crisis and the subsequent threat of a human nvCJD epidemic. In the 'protein-only' hypothesis, the infectious agent, called prion, is assumed to be a misfolded host protein. Transgenesis has mainly been applied to study the role of this protein, its structure-function relationship with respect to its pathogenic properties and to assess the genetic origin of the well-recognised species barrier effect. This approach has somewhat supplemented the lack of in vitro models. This review will try to summarise the impressive work that has been done in this field. Although many questions remain unanswered, transgenic experiments have and will still improve our knowledge on this disease and might help us to develop critically needed therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12509129     DOI: 10.1023/a:1021125510220

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  141 in total

1.  Prions prevent neuronal cell-line death.

Authors:  C Kuwahara; A M Takeuchi; T Nishimura; K Haraguchi; A Kubosaki; Y Matsumoto; K Saeki; Y Matsumoto; T Yokoyama; S Itohara; T Onodera
Journal:  Nature       Date:  1999-07-15       Impact factor: 49.962

2.  Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie.

Authors:  N A Mabbott; F Mackay; F Minns; M E Bruce
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

3.  Altered circadian activity rhythms and sleep in mice devoid of prion protein.

Authors:  I Tobler; S E Gaus; T Deboer; P Achermann; M Fischer; T Rülicke; M Moser; B Oesch; P A McBride; J C Manson
Journal:  Nature       Date:  1996-04-18       Impact factor: 49.962

Review 4.  Transgenic analysis of prion diseases.

Authors:  R C Moore; D W Melton
Journal:  Mol Hum Reprod       Date:  1997-06       Impact factor: 4.025

Review 5.  Detection of cattle-derived BSE prions using transgenic mice overexpressing bovine PrP(C).

Authors:  A Buschmann; E Pfaff; K Reifenberg; H M Müller; M H Groschup
Journal:  Arch Virol Suppl       Date:  2000

6.  Scrapie in mice deficient in apolipoprotein E or glial fibrillary acidic protein.

Authors:  J Tatzelt; N Maeda; M Pekny; S L Yang; C Betsholtz; C Eliasson; J Cayetano; A P Camerino; S J DeArmond; S B Prusiner
Journal:  Neurology       Date:  1996-08       Impact factor: 9.910

Review 7.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

8.  Mice devoid of PrP are resistant to scrapie.

Authors:  H Büeler; A Aguzzi; A Sailer; R A Greiner; P Autenried; M Aguet; C Weissmann
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

9.  Doxycycline control of prion protein transgene expression modulates prion disease in mice.

Authors:  P Tremblay; Z Meiner; M Galou; C Heinrich; C Petromilli; T Lisse; J Cayetano; M Torchia; W Mobley; H Bujard; S J DeArmond; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

10.  Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein.

Authors:  H Büeler; M Fischer; Y Lang; H Bluethmann; H P Lipp; S J DeArmond; S B Prusiner; M Aguet; C Weissmann
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

View more
  1 in total

1.  Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC.

Authors:  Sandra Müller; Roland Kehm; Michaela Handermann; Nurith J Jakob; Udo Bahr; Björn Schröder; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.